Double-digit sales dip in anti-infective segment to weigh on Alkem Labs

Higher chronic sales, US market could offset some of the weakness in sales growth

Even as the BSE Healthcare sector has made substantial gains since the start of lockdown, India’s sixth-largest domestic health care company, Alkem Labora-tories, is lagging peers. The firm has given a return of 24 per cent, against the 78 per cent gain for the BSE Healthcare index since March 23. The lower returns in the market reflect the operational performance of the firm in recent months.  For the trailing 12 months ended August, the  sales were down nearly 8 per cent; the pharmaceutical market witnessed only a little over 2 per cent decline during that period. The reason: Sales of